PI3K beta inhibitor (Gilead)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamePI3K beta inhibitor (Gilead)
Drug Alias Namephosphoinositide-3 kinase beta inhibitor (Calistoga)PI3K beta inhibitor (Calistoga)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase beta inhibitors
TargetsPhosphatidylinositol 3 kinase beta
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCalistoga Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCalistoga Pharmaceuticals IncGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A